Changes in Beneficial Ownership · 4
Opus Genetics, Inc.
IRDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Opus Genetics, Inc.
- Issuer CIK
- 0001228627
- Trading symbol
- IRD
Reporting owner 1
- Name
- YERXA BENJAMIN R
- Reporting owner CIK
- 0001145910
- Relationship
- Director · Officer
- Officer title
- President
- Address
- C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-23 | S · Form 4[F1] | 7,669 | D | 3.5514[F2] | 696,437 | D |
| Common Stock | 2026-10-23 | S · Form 4[F1] | 25,520 | D | 3.5317[F3] | 670,917 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction does not represent a discretionary trade by the Reporting Person.↩ 1↩ 2
- F2
- The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $3.5500 to $3.5522, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F3
- The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.545, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Amy Rabourn, by Power of Attorney
- Date
- 2026-10-27
Company context
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.